Journal Scans
Oral Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Patients With BRCA1 or BRCA2 Mutations and Advanced Breast Cancer: A Proof-of-Concept Trial
Olaparib in BRCA1/2 Mutated Advanced Breast Cancer
A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, M Friedlander, B Arun, N Loman, RK Schmutzler, A Wardley, G Mitchell, H Earl, M Wickens, J Carmichael
20100606
2010 Jul 6
Lancet Oncol
Oral Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Patients With BRCA1 or BRCA2 Mutations and Advanced Breast Cancer: A Proof-of-Concept Trial
Lancet Oncol. 2010 Jul 6;[Epub Ahead of Print], A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, M Friedlander, B Arun, N Loman, RK Schmutzler, A Wardley, G Mitchell, H Earl, M Wickens, J Carmichael
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA-deficient cells. A maximum tolerated dose and initial signal of efficacy in BRCA-deficient ovarian cancers have been reported. We therefore assessed the efficacy, safety, and tolerability of olaparib alone in women with BRCA1 or BRCA2 mutations and advanced breast cancer. Methods: Women (aged ≥18 years) with confirmed BRCA1 or BRCA2 mutations and recurrent, advanced breast...
